Walleye Capital LLC Makes New Investment in Zenas BioPharma, Inc. $ZBIO

Walleye Capital LLC acquired a new position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 209,050 shares of the company’s stock, valued at approximately $5,306,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Polar Capital Holdings Plc bought a new stake in Zenas BioPharma during the fourth quarter worth about $38,402,000. Federated Hermes Inc. grew its stake in Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares in the last quarter. EcoR1 Capital LLC bought a new position in Zenas BioPharma in the fourth quarter valued at approximately $28,667,000. NEA Management Company LLC increased its position in shares of Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after purchasing an additional 789,500 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Zenas BioPharma by 723.5% during the 1st quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock worth $7,592,000 after purchasing an additional 341,187 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Guggenheim reissued a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a report on Friday. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wedbush restated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research note on Friday. Finally, Weiss Ratings cut shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.71.

Zenas BioPharma Stock Performance

ZBIO opened at $29.51 on Friday. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma, Inc. has a 12-month low of $13.50 and a 12-month high of $44.60. The business has a 50 day moving average of $26.95 and a 200-day moving average of $23.38. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -3.28 and a beta of -1.03.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. On average, equities research analysts expect that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were purchased at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the acquisition, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.00% of the stock is currently owned by company insiders.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.